Multiple Sclerosis (MS) is an inflammatory neurodegenerative disease, where neural progenitor cell (NPC) transplantation has been suggested as a potential neuroprotective therapeutic strategy. Since the effect of inflammation on NPCs is poorly known, their effect on the survival and functionality of human NPCs were studied. Treatment with interleukin (IL)-6, tumor necrosis factor (TNF)-α and interferon (IFN)-γ did not induced cytotoxicity, but IFN-γ treatment showed decreased proliferation and neuronal migration. By contrast, increased proliferation and inhibition of electrical activity were detected after TNF-α treatment. Treatments induced secretion of inflammatory factors. Inflammatory cytokines appear to modulate proliferation as well as the cellular and functional properties of human NPCs.
Introduction
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) characterized by presence of focal inflammatory lesions associated with oligodendrocyte and neuron damage, astrogliosis, demyelination and axonal degeneration (Weissert, 2013) . In MS lesions, the predominant cell types are T-lymphocytes and macrophages which are involved in the development of tissue damage. Additionally, activated astrocytes and microglia contribute to lesion development by secreting cytokines and other inflammatory mediators (Weissert, 2013) . The demyelinated areas can be partly repaired by remyelination in the early stage of the disease, but this mechanism is impaired in the later stage of the disease (Kremer et al., 2015) . As damage to neurons and oligodendrocytes and failure of the remyelination process are the neuropathological hallmarks of MS, replacement therapies using exogenous neural progenitor cells (NPC) have been suggested to be a promising approach to promote neuroprotection (Pluchino et al., 2009) . In fact, multiple preclinical studies in animal models of MS have shown a beneficial effect of on the disease course (Giusto et al., 2014) . One of the main obstacles in designing transplantation therapies for MS is the inflammatory nature of the disease, which has been shown to hinder endogenous remyelination (Pluchino et al., 2009 ). On the other hand, it has become evident that some degree of neuroinflammation is necessary for remyelination (Yong and Marks, 2010) , since activated immune cells present at the site of damage may produce neurotrophic factors as well as stimulate their production in neurons and glial cells (Dooley et al., 2014) . The transplanted cells will face the same environmental challenge when entering the damaged brain area.
In MS, lymphocytes and macrophages as well as CNS-resident cells such as astrocytes and microglia secrete cytokines and chemokines that may promote the inflammation but are also able to induce direct neuronal damage (Lassmann, 2014) . Interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-6 are classical proinflammatory cytokines that play a major role in the pathogenesis of MS by promoting neuroinflammation as well as inducing neurotoxicity (Ellwardt and Zipp, 2014; Janssens et al., 2015) . All of these cytokines are detected in perivascular lesions of the MS patients (Cannella and Raine, 1995; Schönrock et al., 2000; McFarland and Martin, 2007) . TNF-α and IFN-γ is secreted from the T helper (Th) 1 and Th17 cells, while secretion of IL-6 is associated to astrocytes. Their levels have been shown to increase in the blood and cerebrospinal fluid especially during the active phase of the disease (Martins et al., 2011; Becher et al., 2016) 
